- Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
- Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
- Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
- Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
Mickie Henshall
Independent Director
Mickie Henshall is a change agent and has specialized in transforming private equity-backed and public organizations into strong commercial companies through her talent in brand creation, portfolio development and marketing strategy. She is currently the Chief Marketing Officer at REALM IDx, the parent company of Ambry Genetics and Invicro, focused on ushering in the new field of integrated diagnostics.
For more than 20 years, Mickie has taken technology innovations to commercial success in life science, molecular diagnostic, clinical and hospital markets. Her deep understanding of science and regulatory compliance enabled her to lead Illumina to its first FDA 510(k), and secure FDA to green light Agena’s strategy of a De Novo 510(k) for its oncology liquid biopsy monitoring test.
Mickie’s leadership includes oversight of global markets, having led regional marketing teams in Europe, China and Australia.
“There is enormous potential for Volition to revolutionize the diagnosis of life-altering diseases through its Nu.Q® product portfolio. I look forward to supporting the board and senior leadership team in realizing Volition’s mission.”
Mickie Henshall
Independent Director